ReviewHematology. American Society of Hematology. Education Program2025
The untransfusable patient.
Review in Hematology. American Society of Hematology. Education Program, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Red cell transfusions represent the main treatment of acute blood loss anemia; however, there are patients who are unable or refuse to receive blood products. Further, in all patients, it is essential to only transfuse when the benefits of transfusion outweigh the risks. In those patients who are unable to receive a blood transfusion, it is important to have a multidisciplinary treatment plan. Further, for those patients requiring surgery, it is important to consider the pre-, intra-, and postoperative periods. Many of the principles and strategies outlined in this article can be applied to patients across clinical contexts and are not exclusive to the surgical setting. Before any planned surgery or intervention, all patients should be screened for anemia at least 6 weeks prior to their anticipated surgical or delivery date. Anemia should be corrected, and the patient's bleeding history should be documented. Strategies to reduce blood loss intraoperatively should be discussed with the surgical and anesthetic team. A plan for emergency management of bleeding and treatment to reduce risk, both intraoperatively and postoperatively, should be developed. The patient's decisions about which, if any, blood products or fractions are acceptable should be documented. Intraoperatively, surgical and anesthetic techniques to minimize bleeding should be used along with appropriate medications. Postoperatively, considerations include the minimization of blood sampling, ongoing support of the patient's hemoglobin mass, and optimization of the physiologic tolerance of anemia. Options exist to allow for the safe and effective management of patients who refuse or are unable to receive blood transfusions. It is essential to have clear communication and documentation of the goals of therapy as well as acceptable interventions. The involvement of a multidisciplinary team to manage the patient is essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.